Efficacy of 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch on activities of daily living in severe Alzheimer's disease

SAGE Open Medicine
Joseph L MiccaX Meng

Abstract

Investigate efficacy of 13.3 mg/24 h rivastigmine patch in patients with severe Alzheimer's disease on Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale-Severe Impairment Version items and domains. Retrospective analysis of the 24-week, randomized, double-blind ACTivities of daily living and cognitION (ACTION) study, using factor analysis to establish "best fit" for Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale-Severe Impairment Version items into domains. Treatment differences (13.3 vs 4.6 mg/24 h patch) on items and domains were assessed. Overall, 632 patients provided Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale-Severe Impairment Version data. Factor analysis yielded four domains. The 13.3 versus 4.6 mg/24 h patch demonstrated significantly greater efficacy on "Daily function" (p = 0.038), supported by greatest effect sizes on items within this domain, and trend toward greater efficacy on "Communication" (p = 0.052). No significant between-group differences were observed on "Independence" (p = 0.600) or "Environment" (p = 0.261). The 13.3 mg/24 h patch was superior to 4.6 mg/24 h patch on "Daily function" in severe Alzheimer's disease.

References

Nov 1, 1975·Journal of Psychiatric Research·M F FolsteinP R McHugh
Jan 1, 1993·Health Affairs·D P RiceE Segura
Aug 28, 2001·The Journals of Gerontology. Series B, Psychological Sciences and Social Sciences·D H TaylorF A Sloan
Apr 23, 2002·JAMA : the Journal of the American Medical Association·Kristine YaffeKenneth E Covinsky
Apr 4, 2003·The New England Journal of Medicine·Barry ReisbergUNKNOWN Memantine Study Group
Jan 22, 2004·JAMA : the Journal of the American Medical Association·Pierre N TariotUNKNOWN Memantine Study Group
Sep 24, 2004·Health and Quality of Life Outcomes·Christian K AndersenPer Kragh-Sørensen
Apr 4, 2006·Lancet·Bengt WinbladUNKNOWN Severe Alzheimer's Disease Study Group
Nov 30, 2006·Alzheimer Disease and Associated Disorders·Howard H FeldmanUNKNOWN Memantine MEM-MD-02 Study Group
Dec 3, 2008·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Nathan Herrmann, Serge Gauthier
Sep 3, 2010·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Somaia MohamedLon S Schneider
Feb 2, 2011·American Journal of Alzheimer's Disease and Other Dementias·George GrossbergJason T Olin
Feb 4, 2011·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Ralf IhlUNKNOWN WFSBP Task Force on Treatment Guidelines for Alzheimer's Disease and other Dementias
Nov 10, 2011·International Journal of Geriatric Psychiatry·Martin R FarlowMonique Somogyi
Mar 9, 2012·The New England Journal of Medicine·Robert HowardPatrick Phillips
Aug 29, 2013·American Journal of Alzheimer's Disease and Other Dementias·George GrossbergChristine Strohmaier

❮ Previous
Next ❯

Citations

Sep 24, 2015·The Cochrane Database of Systematic Reviews·Jacqueline S BirksJohn Grimley Evans

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT00948766
NCT00099242
NCT00506415
NCT00866060

Software Mentioned

Statistical Analysis Software

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.